The hSNF5/INI1 gene encodes a member of the SWI/ SNF chromatin remodelling complexes. It was recently identified as a tumour suppressor gene mutated in sporadic and hereditary Malignant Rhabdoid Tumours (MRT). However, the role of hSNF5/INI1 loss-offunction in tumour development is still unknown. Here, we show that the ectopic expression of wild-type hSNF5/ INI1, but not that of truncated versions, leads to a cell cycle arrest by inhibiting the entry into S phase of MRT cells. This G1 arrest is associated with down-regulation of a subset of E2F targets including cyclin A, E2F1 and CDC6. This arrest can be reverted by coexpression of cyclin D1, cyclin E or viral E1A, whereas it cannot be counteracted by pRB-binding deficient E1A mutants. Moreover, hSNF5/INI1 is not able to arrest cells lacking a functional pRB. These observations suggest that the hSNF5/INI1-induced G1 arrest is dependent upon the presence of a functional pRB. However, the observation that a constitutively active pRB can efficiently arrest MRT cells indicates that hSNF5/INI1, at the difference of the ATPase subunits of the SWI/SNF complex, is dispensable for pRB function. Altogether, these data show that hSNF5/INI1 is a potent regulator of the entry into S phase, an effect that may account for its tumour suppressor role.
Introduction
The hSNF5/INI1 gene, also termed SMARCB1 or BAF47, was initially identified as encoding a human homologue of the yeast SNF5 protein and a HIV integrase interactor (Kalpana et al., 1994; Muchardt et al., 1995) . More recently, it was characterized as a tumour suppressor gene inactivated in very aggressive childhood cancers termed Malignant Rhabdoid Tumours (MRT). Indeed, a positional cloning strategy targeting the chromosome 22 abnormalities observed in MRT revealed that this gene was bi-allelically inactivated in most, if not all, MRT as a result of homozygous deletions or truncating non-sens or frameshift mutations (Versteege et al., 1998) . Subsequently, constitutional mutations of this gene were identified in at risk individuals from cancer-prone families (Biegel et al., 1999; Savla et al., 2000; Sevenet et al., 1999b; Taylor et al., 2000) . The inactivation of hSNF5/INI1 therefore follows the two-hits recessive model of oncogenesis with two distinct somatic mutations in sporadic cases and a germline mutation associated with a somatic mutation in hereditary cases. The spectrum of tumours demonstrating loss-offunction of hSNF5/INI1 includes MRT but also a subset of choroid plexus carcinoma, medulloblastoma and central primitive neuroectodermal tumours (Biegel et al., 2000; DeCristofaro et al., 1999; Sevenet et al., 1999a) . In agreement with hSNF5/INI1 being a tumour suppressor gene, three different groups very recently reported the occurrence of tumours resembling MRT in mice harbouring an inactivated mSnf5 allele (Guidi et al., 2001; Klochendler-Yeivin et al., 2000; Roberts et al., 2000) .
The hSNF5/INI1 protein is a subunit of the phylogenetically conserved SWI/SNF complexes that play a key role in transcriptional regulation through an ATP-dependent chromatin remodelling process . In human, different SWI/ SNF complexes can be distinguished based on their ATPase subunit, being either hBRM or BRG1, and on the number and characteristics of associated proteins (Nie et al., 2000; Wang et al., 1996) . Interestingly, hSNF5/INI1 appears as an integral component of these various complexes. The reconstitution of SWI/SNF complexes using purified subunits has shown that BRG1 or hBRM are sufficient to promote nucleosomal remodelling in vitro. The addition of hSNF5/INI1, BAF155 and BAF170 increases this basal activity to levels similar to that of immunopurified SWI/SNF complexes (Phelan et al., 1999) . The SWI/SNF complexes have been shown to be necessary for the transcriptional activation of numerous genes, however, recent studies strongly suggest that they may also be involved in transcriptional repression (Sudarsanam and Winston, 2000) . In that respect, mounting evidence indicates that the SWI/SNF complexes have an essential role in the retinoblastoma protein (pRB)-mediated repression of E2F target genes. Indeed, BRG1 and hBRM interact and cooperate with the pRB tumour suppressor to repress E2F1 activity (Dunaief et al., 1994; Trouche et al., 1997) . Recent data suggest that different complexes of pRB with histone deacetylases and SWI/SNF coordinate the sequential activation of E2F targets which drives the progression from the G1 to S phase (Zhang et al., 2000) . The functional link between E2F and SWI/SNF is further supported by results from a genetic screen in Drosophila for enhancers of dE2F1 phenotype, which identified members of the SWI/SNF complexes as negative regulators of E2F activity (Staehling-Hampton et al., 1999) .
In this study, we have investigated the role of hSNF5/INI1 in the regulation of the cell cycle. We show that the ectopic expression of hSNF5/INI1 in deficient MRT cells induces a cell cycle arrest by inhibition of the entry into S phase. The SNF5 homology domain is necessary but not sufficient to mediate this effect. Cotransfection experiments in MRT cells and analyses of the effect of hSNF5/INI1 overexpression in various cell lines highlight the role of pRB in the hSNF5/INI1-mediated G1 arrest. Finally, we show that the ectopic expression of hSNF5/INI1 in MRT leads to the down-regulation of a subset of E2F target genes including cyclin A, E2F1 and CDC6.
Altogether, these results provide a functional basis for the mechanism of action of the hSNF5/INI1 tumour suppressor gene.
Results
Wild-type hSNF5/INI1 but not cancer-related deletion mutants, inhibits the entry into S phase of MRT cells
The effect of hSNF5/INI1 ectopic expression on three different MRT cell lines was investigated. MON and G401 are characterized by a complete homozygous deletion of the hSNF5/INI1 gene and KD harbours a complete deletion of one allele and a deletion of exon 4 and 5 of the other allele (Versteege et al., 1998) . These cell lines were transfected with expression vectors encoding either a tagged version of wild-type hSNF5/ INI1 (HA-INI1) or GFP (green fluorescent protein) then labelled with BrdU to monitor DNA synthesis. Cells expressing HA-INI1 were revealed by immunofluorescence with an anti-HA antibody. HA-INI1 and GFP positive cells were analysed for BrdU incorporation. In all three cell lines, the amount of cell displaying BrdU incorporation was dramatically reduced in HA-INI1 as compared to GFP expressing cells (Figure 1a ). The MON cell line, which exhibited the highest transfection efficiency, was used to more precisely document the cell cycle distribution of HA-INI1 expressing cells. MON cells were cotransfected with HA-INI1 or pcDNA together with the pPUR puromycine resistance gene. After selection of puromycin resistant cells for 24 -48 h and double-staining with propidium iodide and BrdU, FACS analyses were performed. The amount of cells in G1 was strongly increased and that of cells in S phase dramatically reduced in MON cells expressing HA-INI1 as compared to those transfected with the empty vector ( Figure 1b) . Similar experiments were conducted with vectors encoding deletion mutants of the HA-INI1 protein.
Indeed, most point mutations observed in MRT are frameshift or non-sens, and therefore result in the truncation of the C-terminal end of the protein (Sevenet et al., 1999a) . The HA-INI1D2 and HA-INI1D3 deletion mutants (Muchardt et al., 1995) therefore mimic cancer-related alterations (Figure 2a) . In contrast to the strong inhibition of DNA synthesis induced by HA-INI1 in MON cells, no detectable effects on the BrdU incorporation was noticed with HA-INI1D2 (Figure 2b ). The HA-INI1D3 mutant, which harbours a C-terminal deletion of 56 amino acids, only demonstrated a minor but reproducible inhibition of the S phase ( Figure 2b ). These experiments indicated that the C-terminal deletion mutants are impaired in their ability to induce a G1 arrest and that the SNF5 homology domain, including the Cterminal coil-coiled, is necessary for a full effect of hSNF5/INI1 on MRT cells. However, this domain was not sufficient since the HA-INI1D1 mutant, which encodes the C-terminal part of the protein but lacks its N-terminal portion was also unable to inhibit S phase entry. Western blot analyses indicated that the expression levels of the wild-type HA-INI1 and of the different mutants were similar (Figure 2c ).
Similar transfection experiments were conducted in Hela cells, which express an endogenous wild-type hSNF5/INI1 (data not shown). An expression level of HA-INI1 similar to that described above in MON cells did not lead to any modification of the cell cycle (Figure 2b, c) . This indicated that the cell cycle arrest induced by HA-INI1 in MRT cells is not linked to a general toxic effect of the protein.
Finally, in agreement with the observation of an HA-INI1 mediated cell cycle arrest in MRT but not in Hela cells, we could not obtain MON cells stably expressing this protein whereas previous reports mentioned stable expressions of tagged INI1 constructs in Hela cells (Sif et al., 1998) .
Altogether these data show that the wild-type hSNF5/INI1 but not the cancer-related truncated mutants, inhibits the proliferation of MRT cells through a block of the entry into S phase.
The S phase inhibition induced by HA-INI1 in MRT cells can be rescued by expression of cyclin D1, cyclin E and E1a
The entry into S phase is tightly regulated by cyclin D1/CDK4-6 and cyclin E/CDK2 complexes. We therefore investigated whether the overexpression of these proteins could modify the effect of HA-INI1. MON cells cotransfected with pPUR, HA-INI1 and other relevant expression vectors were selected by hSNF5/INI1 induces a G1 arrest I Versteege et al puromycine for 24 h and the BrdU incorporation was studied by flow cytometry. As shown in Figure 3 , the expression of cyclin D1 or cyclin E, but not that of CDK4 or CDK2, was able to completely abrogate the S phase inhibition induced by HA-INI1. A major role of cyclin D1/CDK4 and cyclin E/ CDK2 complexes is the sequential phosphorylation of the pRB protein leading to the disruption of pRB-E2F complexes and therefore to the activation of E2F target genes (Harbour et al., 1999; Lundberg and Weinberg, 1998) . Since pRB is consistently expressed in MRT cells (data not shown), we used the adenoviral E1A protein to inhibit its activity and to evaluate its role on HA-INI1-induced cell cycle arrest. Indeed, one of the hSNF5/INI1 induces a G1 arrest I Versteege et al effects of E1A is to bind pocket proteins, including pRB, and to displace them from E2F via the CR1 region (Gallimore and Turnell, 2001) . The coexpression of wild-type E1A was able to completely relieve the cell cycle arrest induced by HA-INI1 (Figure 4) . In contrast, the expression to similar levels of a mutated version of E1A, lacking the CR1 domain, did not counteract the HA-INI1 effect. Similarly, the expression of E1ARBmut, in which amino-acids 38 -44 have been converted to alanine, abrogating pRB-binding in CR1 (Trouche and Kouzarides, 1996) , was unable to revert HA-INI1-induced S phase inhibition (Figure 4 ). Altogether these cotransfection experiments indicated that wild-type E1A, cyclin D1 and cyclin E expression were dominant upon HA-INI1 to induce DNA synthesis. They also suggested that pRB plays a critical role in hSNF5/INI1-induced S phase inhibition.
Study of the overexpression of HA-INI1 in non MRT cell lines
To further study the putative role of pRB on HA-INI1-induced cell cycle arrest, we transfected HA-INI1 in different cell lines with an abnormal pRB pathway. The SAOS-2 cell line is derived from an osteosarcoma and expresses a C-terminal truncated pRB protein (Shew et al., 1990) . The MDA-MB-468 breast cancer cell line harbours a homozygous deletion of the pRB locus (Herrera et al., 1988) . U2OS osteosarcoma cells lack the p16 INK4A inhibitor of the cyclin D1/CDK4 complex and therefore express an hyperphosphorylated pRb protein (Craig et al., 1998; Kamb et al., 1994) . Previous results have shown that coexpression of pRb and BRG1 but not expression of pRb alone can arrest U2OS cells suggesting that the pRb pathway is altered in these cells (Zhang et al., 2000) . Given the variable puromycin resistance of the three cell lines, a slightly different approach from that above-mentioned for MON cells was used. In brief, cells were cotransfected with pBOS-H2BGFP encoding an H2BGFP fusion protein, and relevant expression vectors in a 1/5 ratio, then labelled by propidium iodide. GFP positive cells were analysed by flow cytometry. As shown in Figure  5 , the expression of a constitutively active pRB (RB-P) (Xiao et al., 1995) efficiently blocked the entry into S phase of SAOS-2 and MDA-MB-468 cells as evidenced by an increase of cells in G1 and a decrease of S phase ( Figure 5 ). In contrast, wild-type HA-INI1, similarly to truncated HA-INI1D2, had no effect on the cell cycle distribution of these cells. For U2OS cells, a significant increase of the G1 associated with a decrease of S and M phases could be induced by p16
INK4A but not by HA-INI1. Together with the above-mentioned results obtained in Hela cells, in which pRB is functionally inactivated by the presence of HPV18 E7, these data suggest that HA-INI1 is unable to induce a cell cycle arrest in cells harbouring a deficient pRB pathway. It has been shown that pRB is unable to mediate a cell cycle arrest in BRG1 deficient cells suggesting that the SWI/SNF complex is an essential partner of the pRB pathway (Strobeck et al., 2000; Zhang et al., 2000) . It was therefore tempting to speculate that hSNF5/INI1, which is an integral member of this complex, may also be necessary for pRB effect. However, cotransfection experiments with the pPUR and RB-P vectors showed that pRB could efficiently inhibit BrdU incorporation in MON cells. Similarly, p16 INK4A could induce a G1-arrest in MON cells (Figure 6 ). These data indicate that hSNF5/INI1 is not required for pRB-induced G1 arrest of MRT cells.
HSNF5/INI1 modulates cyclin A, E2F1 and CDC6 expression in MRT cells
Since wild-type HA-INI1 induces a G1 arrest in MRT cells, we were interested to study the effect of HA-INI1 on the expression level of various regulators of the cell cycle. MON cells were cotransfected with pPUR and either HA-INI1 or HA-INI1D2. After selection with puromycin, immunoblot and competitive RT -PCR analyses were performed (Figure 7) . Among upstream regulators of the pRB pathway, cyclin D1, cyclin E, CDK2 and CDK4 exhibited no significant change upon HA-INI1 expression. Similarly, p16
INK4A , p27 KIP1 and p21 CIP1 expression levels were stable. Among downstream E2F-target genes, B-myb, similarly to cyclin E and CDK2 did not change significantly. In contrast, the levels of cyclin A, E2F1 and CDC6 were dramatically reduced. The observation that the transcripts encoding the latter proteins were also down-regulated suggests that the regulation occurs at the transcription level.
Discussion
Recent data indicate that hSNF5/INI1, which encodes an integral component of the mammalian SWI/SNF complexes, acts as a tumour suppressor gene in human and mouse (Klochendler-Yeivin et al., 2002) . However, presently, little is known about the precise function of the hSNF5/INI1 protein. In this manuscript, we show that the ectopic expression of hSNF5/INI1 blocks the S phase entry in MRT cells. Interestingly, deletion mutants, mimicking the alterations observed in human tumours, cannot reproduce this effect. This suggests that hSNF5/INI1 is involved in the control of the G1-S transition of the cell cycle and that the loss of this function is critical in hSNF5/INI1-related tumours. hSNF5/INI1 is structurally characterized by the presence of a SNF5 homology domain localized at its C-terminal end. This domain, whose function is unknown, is highly conserved throughout evolution from yeast to human. It is the site of binding of most presently described hSNF5/INI1 interaction partners and it contains as nuclear export signal (Craig et al., 2002; Muchardt et al., 1995) . Our results indicate that the SNF5 domain is necessary but not sufficient to induce a G1 arrest in MRT cells. The pRB pathway is frequently altered in cancer through direct mutation, sequestration by viral proteins or functional inactivation resulting from a deregulated cyclin/CDK pathway. Numerous reports indicate that the SWI/SNF complexes play key roles in the pRBmediated regulation of the cell cycle (KlochendlerYeivin et al., 2002) . Indeed, hBRM and BRG1, the core ATPase subunits of the complexes, can bind to and cooperate with pRB to induce a cell cycle arrest and to regulate E2F activity (Dunaief et al., 1994; Strober et al., 1996; Trouche et al., 1997) . This cooperation is essential, since recent data indicate that pRB cannot induce a cell cycle arrest in the absence of BRG1 and hBRM (Strobeck et al., 2000 (Strobeck et al., , 2001 Zhang et al., 2000) . Reciprocally, BRG1-induced cell cycle arrest is dependent upon the presence of a functional pRB (Strober et al., 1996; Zhang et al., 2000) . These data strongly suggest that the alteration of BRG1 constitutes another mechanism of oncogenesis linked to a functional inactivation of the pRB pathway. In agreement with this hypothesis, inactivating mutations of BRG1 have been observed in cancer cell lines (Wong et al., 2000) . Current models propose that BRG1 is a critical component of pRB-repressor complexes, which regulates the activation of E2F target genes (Dunaief et al., 1994; Strobeck et al., 2001; Trouche et al., 1997; Zhang et al., 2000) . Interestingly, the hSNF5/INI1-mediated cell cycle arrest that we describe shares a number of similarities with that previously observed for BRG1 or hBRM (Shanahan et al., 1999; Zhang et al., 2000) . First, we show that this arrest can be reversed by cyclin D1 or cyclin E, two proteins which are essential for the disruption of pRB-repressor complexes by sequential phosphorylations. Second, our observations that wild-type E1A, but not pRBbinding deficient mutants, abrogates the effect of hSNF5/INI1 and that hSNF5/INI1 cannot arrest cell lines with a deficient pRB pathway, strongly suggest that the hSNF5/INI1-induced arrest is dependent upon the presence of a functional pRB. However, beside these similarities, an important difference has to be mentioned. Indeed, whereas BRG1 or hBRM are required for pRB-mediated cell cycle arrest, we show that hSNF5/INI1 is not since a constitutively active pRB or p16
INK4A are able to arrest hSNF5/INI1 deficient MRT cell lines.
Altogether these data suggest that hSNF5/INI1 and the ATPases subunits of the complexes have essential functions for the SWI/SNF-mediated cell cycle regulation. However, whereas the ATPase subunits are essential cofactors of pRB, hSNF5/INI1 is dispensable. In this respect, it is noteworthy that BRG1 or hBRM have been shown to be sufficient to remodel nucleosomes in vitro and that hSNF5/INI1 increases this remodelling activity (Phelan et al., 1999) . It may be hypothesized that, whereas the ATPase subunits of SWI/SNF are necessary for the chromatin remodelling associated with pRB-mediated repression of E2F, hSNF5/INI1 has a promoting but not primary role on this remodelling. Alternatively, it may suggest that hSNF5/INI1 function is partly independent of the ATPase subunits. In that respect, it would be interesting to analyse if the hSNF5/INI1-induced G1-arrest is genetically dependent upon the presence of a functional SWI/SNF complex.
Presently, the cell cycle effects of SWI/SNF proteins have only been studied in cancer cell lines harbouring known abnormalities of the SWI/SNF genes or of the pRB pathway. It cannot be excluded that additional genetic abnormalities present in these cell lines might also interfere with the cell cycle effects of the SWI/SNF subunits. In that respect, the analysis of hSNF5/INI1 or BRG1 cell cycle effects on mouse embryo fibroblasts harbouring single genetic abnormalities would be of major interest.
We also investigated the expression of various cell cycle regulators upon hSNF5/INI1 expression. We did not observe significant modifications of the expression of a number of upstream regulators of the pRB pathway, including CDK2, CDK4 and major inhibitors of cyclin/CDK complexes. Based on the abovementioned function of SWI/SNF in pRB-mediated repression of E2F target genes and on the genetic interaction in Drosophila between SWI/SNF and E2F (Staehling-Hampton et al., 1999) , we also analysed various E2F target genes. Interestingly, the expression of CDC6, cyclin A and E2F1 was strongly decreased both at the mRNA and protein levels whereas that of cyclin E, B-myb or CDK2 was not modified, suggesting that hSNF5/INI1, similarly to BRG1, is involved in the regulation of a subset of E2F target genes (Strobeck et al., 2000; Zhang et al., 2000) . Further experiments will be important to determine whether this down-regulation is linked to a direct corepressor effect of hSNF5/INI1 or if it is an indirect consequence of the G1 arrest. Ongoing micro-array experiments should also enable to achieve a more general overview of genes up-or down-regulated by hSNF5/INI1.
Growing evidence implicates the SWI/SNF complex in oncogenesis. Indeed, mutations of hSNF5/INI1 are associated with sporadic and hereditary cases of MRT and BRG1 truncating mutations have been observed in tumour cell lines (Wong et al., 2000) . Moreover, in mouse, the heterozygosity for mSnf5 or mBrg1 mutations predisposes to cancer (Bultman et al., 2000; Guidi et al., 2001; Klochendler-Yeivin et al., 2000; Roberts et al., 2000) . Together with recent reports focusing on BRG1, our data strongly suggest that the loss-of-function of SWI/SNF components promotes oncogenesis through a deficient regulation of the cell cycle.
Materials and methods

Cells and expression vectors
MON cells were maintained in RPMI 1640 medium, and Hela, SAOS-2, MDA-MB-468 and U2OS cells in Dulbecco's modified Eagle's medium (DMEM). Media were supplemented with 10% foetal calf serum, 100 units/ml penicillinstreptomycin (Invitrogen, Groningen, The Netherlands), 2 mM L-glutamine (Invitrogen, Groningen, The Netherlands). MDA-MB-468 cells were supplemented with non-essential amino acids (Invitrogen, Groningen, The Netherlands).
hSNF5 constructs in pcDNA (HA-INI1, HA-INI1D1, HA-INI1D2, HA-INI1D3) and E1A constructs in pBJ9 (E1A12S, E1ADCR1, E1ARBmut) used in this study have been described previously (Muchardt et al., 1995; Trouche and Kouzarides, 1996) . Expression vectors for cyclin D1 (pCMV-D1), cyclin E (pRC CMV cyclin E), CDK2 (pRC CMV CDK2), CDK4 (pcDNA CDK4), RB-P a version mutated on cyclin phosphorylation sites (Hamel et al., 1992) and p16
INK4a were kindly provided by Pierre Savatier, Didier Trouche, Annick Harel-Bellan and Christian Larsen, respectively.
pBOS-H2BGFP, pPUR and pEGFP-C1 vectors were obtained from BD, Pharmingen (San Diego, CA, USA) and Clontech (Palo Alto, CA, USA), respectively.
BrdU incorporation and FACS (fluorescence activated cell sorter) analysis
Approximately 1610 6 cells were plated in 10-cm dishes 24 h before transfection. Cells were cotransfected by the Effectene method (Qiagen GmbH, Germany) with pPUR selection vector (0.35 mg) and indicated expression vectors (3.15 mg). Twenty-four hours after transfection, cells were selected with puromycin (Clontech, Palo Alto, CA, USA) at 2 mg/ml for 24 h then labelled with BrdU for 30 min at 378C. Cells fixed in 70% ethanol and stained with an anti-BrdU antibody (Harlan Sera-Lab, Hillcrest, UK) and with propidium iodide (PI) (Sigma-Aldrich, St. Louis, MA, USA) were analysed on a Becton Dickinson FACSscan as previously described (Dauphinot et al., 2001; Remvikos et al., 1991) .
A similar protocol was used for cotransfection experiments with the pBOS-H2BGFP expression vector (0.7 mg) and indicated expression vectors (2.8 mg). Forty-eight hours post transfection, cells were washed with PBS, fixed in ethanol 70% then labelled with PI. The GFP positive cells were analysed for cycle distribution.
Immunofluorescence staining
Cells were grown in Labtech cell culture chambers (Invitrogen, Groningen, The Netherlands). Forty-eight hours after transfection, cells were washed with PBS and fixed in 3% Paraformaldehyde for 20 min. Permeabilization was carried out in 0.2% Triton for 5 min. After incubation for 10 min in 25 mM Tris-HCl pH 8, 125 mM NaCl, 0.15% Tween 20, supplemented with 5% milk powder, the labelling was carried out by incubation for 1 h with a mouse monoclonal anti-HA antibody (clone 16 B6 from BabCO, Richmond, CA, USA) followed by a 1 h incubation with a FITC conjugated goat anti-mouse IgG (APBiotech, Buckinghamshire, UK). After denaturation in 4 N HCL for 10 min and extensive wash in PBS, cells were incubated during 10 min in PBS containing 5% BSA and 0.1% Tween 20. BrdU labelling was carried out in the same buffer with the monoclonal rat anti-BrdU (Harlan Sera-Lab, Hillcrest, UK) then revealed with Texas For antibody detection, horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies were used (APBiotech, Buckinghamshire, UK) and detected by enhanced chemiluminescence (Roche, Basel, Switzerland) according to the manufacturer's instructions.
RT -PCR analysis
Total mRNA were extracted using the Trizol reagent according to the manufacturer's instructions (Gibco-BRL). Total RNAs were reverse-transcribed with oligo-dT using the GeneAmp RNA PCR kit (Applied Biosystems). The resulting cDNAs were co-amplified with 1.9 pmoles of primers for GAPDH as internal control and 15 pmoles of primers for each tested transcript. The PCR reactions (30 cycles) included denaturation at 948C for 30 s, annealing at 588C for 30 s and extension at 728C for 1 min.
